Is Egrifta (Tesamorelin) Legal in Illinois?

What Is Tesamorelin and Why Does Its Classification Matter?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Administered subcutaneously, it stimulates the pituitary gland to secrete endogenous growth hormone in a pulsatile, physiologic pattern rather than delivering exogenous GH directly [1]. The legal classification matters because the method by which a drug reaches a patient, whether through brand-name dispensing, 503A compounding, or 503B outsourcing, is determined almost entirely by that drug's regulatory standing at the federal level.

How Tesamorelin Differs From Direct GH

Direct recombinant human growth hormone (rhGH), such as somatropin, is a Schedule III controlled substance under certain formulations and faces far tighter DEA and state-level scrutiny [2]. Tesamorelin, as a GHRH analog, is not scheduled. That distinction makes its legal path in Illinois meaningfully different from the one surrounding somatropin prescriptions.

The FDA-Approval Foundation

The FDA granted original approval for tesamorelin (Egrifta) on November 10, 2010, under NDA 022505 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [3]. A reformulated subcutaneous version, Egrifta SV, received approval on November 28, 2017, offering a more stable formulation at 2 mg per vial [4]. Both approvals sit in the FDA's drug database as legitimate, branded, commercially available medications. That approval record is the starting point for every legal analysis in Illinois or any other state.

Federal Law: The Framework That Illinois Operates Inside

Illinois does not maintain a parallel drug-approval system. The state defers entirely to federal FDA approval for determining whether a drug may be legally marketed, prescribed, and dispensed within its borders.

FDA Approval and the FDCA

The Food, Drug, and Cosmetic Act (FDCA) prohibits introducing a new drug into interstate commerce without an approved New Drug Application [5]. Because Egrifta SV holds NDA 022505, it clears this requirement. A licensed Illinois prescriber may write a prescription for Egrifta SV, a licensed Illinois pharmacy may dispense it, and a patient may possess and use it, all without any additional state-level drug-law analysis.

DEA Scheduling

The Drug Enforcement Administration's Controlled Substances Act does not schedule tesamorelin [6]. It is not a List I or List II chemical. It does not appear in DEA regulations as an anabolic steroid analog or peptide hormone subject to special handling. Prescribing, dispensing, and possessing Egrifta SV in Illinois therefore requires no DEA-registration-specific prescribing authority beyond what a standard Illinois medical license already provides.

FDA's Position on Compounded Tesamorelin

This is where the legal field tightens considerably. Section 503A of the FDCA governs traditional compounding pharmacies; Section 503B governs outsourcing facilities [7]. Both sections prohibit compounding a drug that is "essentially a copy" of an FDA-approved drug unless that drug appears on an FDA-designated bulk-ingredient list or a clinical-difference finding exists [8].

Tesamorelin does not currently appear on FDA's 503A Bulks List or the 503B Bulks List as a permissible compounding ingredient [9]. The FDA has also not issued a clinical-difference exemption for tesamorelin. This means a 503A compounding pharmacy in Illinois may not legally produce and dispense compounded tesamorelin for individual patients, and a 503B outsourcing facility may not produce it in bulk. Any Illinois pharmacy claiming to legally compound tesamorelin as a workaround to brand-name Egrifta SV pricing should be viewed with caution.

Illinois State Law: What the Prairie State Adds

Illinois does not add a separate drug-approval layer, but several state statutes shape how Egrifta SV reaches patients in practice.

Illinois Controlled Substances Act (720 ILCS 570)

The Illinois Controlled Substances Act mirrors the federal DEA schedule in most respects and adds some state-specific substances [10]. Tesamorelin appears in neither the federal nor Illinois schedules. A standard Illinois-licensed physician, physician assistant, or advanced practice registered nurse with prescribing authority may write for Egrifta SV on a standard, non-controlled prescription pad. No triplicate form, no special DEA-controlled ordering process.

Illinois Pharmacy Practice Act (225 ILCS 85)

The Illinois Pharmacy Practice Act requires that any drug dispensed to an Illinois patient come from a pharmacy licensed by the Illinois Department of Financial and Professional Regulation (IDFPR) or from an out-of-state pharmacy holding a valid Illinois non-resident pharmacy permit [11]. Egrifta SV dispensed from a mail-order specialty pharmacy licensed in a different state is fully legal as long as that pharmacy holds the Illinois non-resident permit and the prescription is valid.

Illinois Medical Practice Act (225 ILCS 60)

Off-label prescribing is explicitly within the scope of a physician's discretion under the Illinois Medical Practice Act, consistent with national standards [12]. The American Association of Clinical Endocrinology (AACE) notes that "off-label prescribing is a legitimate and sometimes necessary aspect of medical practice when supported by clinical evidence" [13]. A physician prescribing tesamorelin off-label for, say, age-related GH decline or body composition in a non-HIV patient is not violating Illinois law, though payer reimbursement for off-label use is a separate, practical issue.

Illinois Telehealth Act (20 ILCS 3960)

Illinois expanded telehealth prescribing authority meaningfully after 2020. Under the Illinois Telehealth Act, a licensed prescriber may evaluate a patient via synchronous audio-video technology and issue a valid prescription, including for Egrifta SV, without an in-person visit provided the standard of care for the initial evaluation is met [14]. The Illinois Department of Public Health has confirmed that telehealth encounters satisfying the standard of care create a valid physician-patient relationship sufficient for prescribing [15].

How to Get Egrifta (Tesamorelin) in Illinois

Getting a legal tesamorelin prescription in Illinois follows a clear pathway. The steps are not complicated, but each one matters.

Step 1: Establish a Valid Prescriber Relationship

A board-certified physician, endocrinologist, or infectious disease specialist (in HIV contexts) must evaluate the patient. That evaluation may occur in-person or via a qualifying telehealth encounter under Illinois law. The clinician reviews symptoms, orders baseline labs (IGF-1, fasting glucose, HbA1c, lipid panel), and documents medical necessity.

Step 2: Obtain the Prescription

For the FDA-approved indication (HIV lipodystrophy), the standard dose is tesamorelin 2 mg subcutaneously once daily [3]. The prescriber writes for Egrifta SV 2 mg/vial, with a 30- or 90-day supply, from an IDFPR-licensed or Illinois-permitted pharmacy. No DEA controlled-substance prescription form is required.

Step 3: Specialty Pharmacy Dispensing

Egrifta SV is typically dispensed through specialty pharmacies due to cold-chain storage requirements. The manufacturer, Theratechnologies, operates a patient-assistance program (Egrifta SV Access Program) that may reduce out-of-pocket cost for qualifying patients [4]. Insurance coverage under Illinois-regulated health plans is generally limited to the on-label HIV lipodystrophy indication; prior authorization is almost universally required.

Step 4: Patient Training and Storage

Egrifta SV must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) before reconstitution. After reconstitution, it should be used within 24 hours [3]. Illinois patients receiving mail-order supply should confirm the specialty pharmacy uses validated cold-chain shipping.

Clinical Evidence Supporting Tesamorelin Use

Understanding the evidence behind tesamorelin helps patients and prescribers evaluate its use in appropriate contexts.

Phase III Trial Data in HIV Lipodystrophy

Two key Phase III randomized controlled trials (ENCORE studies, combined N=816) demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 18% versus 2% for placebo at 26 weeks, measured by CT scan (P<0.001) [16]. Trunk fat reduction was also significant, with no clinically meaningful change in subcutaneous fat. This body of evidence supported the FDA approval and remains the regulatory anchor for the drug's approved labeling.

Cognitive and Metabolic Outcomes

A 2018 randomized controlled trial published in Clinical Infectious Diseases (N=353) found that tesamorelin improved cognitive function scores in HIV-positive adults over 36 weeks compared to placebo (P<0.05) [17]. A separate metabolic analysis showed that tesamorelin treatment was associated with a statistically significant reduction in triglycerides (-50 mg/dL, P<0.01) versus placebo in the same population [17].

Non-HIV Populations: What the Evidence Shows

A 2012 study in the Journal of Clinical Endocrinology and Metabolism (N=152) examined tesamorelin in non-HIV adults with abdominal adiposity and found a 10.4% reduction in VAT versus 1.1% for placebo at 26 weeks (P<0.001), though the FDA has not approved this indication [18]. This study is frequently cited in off-label clinical discussions. Prescribers relying on it for off-label use should document the evidence base and the patient-specific clinical rationale.

Safety Profile and Illinois Prescribing Considerations

Common Adverse Effects

The Egrifta SV prescribing information lists the most common adverse reactions as injection-site erythema (8.4%), peripheral edema (6.3%), arthralgia (4.6%), and myalgia (2.0%) [3]. Fluid retention typically resolves with dose reduction or discontinuation.

Glucose and IGF-1 Monitoring

Tesamorelin raises IGF-1 levels. Patients with elevated baseline IGF-1 or active malignancy are not candidates [3]. The FDA label recommends monitoring IGF-1 and fasting glucose at baseline and periodically during treatment. Illinois prescribers should align with FDA labeling on monitoring frequency, checking IGF-1 at 3 months and every 6 months thereafter.

Contraindications

Absolute contraindications under the FDA label include active malignancy, pregnancy, hypersensitivity to tesamorelin or mannitol, and disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor [3]. The FDA label also notes that patients with active or recent acute illness should not begin tesamorelin therapy [4].

What Illinois Patients Should Know About "Research Chemical" Tesamorelin

Some online vendors sell tesamorelin labeled "for research use only" as an apparent legal workaround. This pathway carries real risk in Illinois.

Federal Misbranding and Adulteration Rules

The FDCA prohibits selling an unapproved drug for human use, full stop [5]. A vendor claiming "research only" does not change the legal exposure for the buyer if the product is intended for human self-administration. The FDA has issued multiple warning letters to peptide vendors for exactly this pattern [9].

Illinois Consumer Fraud and Deceptive Business Practices Act (815 ILCS 505)

Illinois Attorney General enforcement under the Consumer Fraud Act has targeted sellers of unverified health products [19]. Purchasing tesamorelin from an unlicensed vendor exposes Illinois residents to both federal FDCA risk and potential state consumer-protection complications if the product is mislabeled or adulterated.

Quality and Purity Concerns

Independent testing of peptides sold through research-chemical channels has found significant variation in purity, concentration, and sterility. A 2023 analysis by the United States Pharmacopeia (USP) highlighted that peptide products outside the regulated pharmaceutical supply chain frequently fail identity and purity specifications [20]. Using sub-potent or contaminated product carries direct patient safety risk beyond any legal concern.

Telehealth Prescribing for Tesamorelin in Illinois: Practical Notes

Illinois telehealth law permits a fully remote initial evaluation for Egrifta SV, provided the encounter meets the standard of care. Practically, that means:

• A synchronous audio-video visit (not asynchronous messaging alone) for the initial prescription [14].
• Baseline labs drawn at a local Illinois laboratory before or concurrent with the telehealth visit.
• A documented clinical indication in the medical record.
• A prescription transmitted electronically to an IDFPR-licensed or Illinois-permitted specialty pharmacy.

Refill prescriptions may, at the prescriber's discretion, use asynchronous lab review in many cases, consistent with Illinois Department of Insurance guidance on telehealth continuity of care [15].

Summary of the Illinois Legal Framework for Tesamorelin

The table below captures the key regulatory checkpoints for tesamorelin in Illinois.

| Legal Dimension | Status in Illinois | |---|---| | FDA approval | Yes (Egrifta SV, NDA 022505) | | DEA schedule | Unscheduled | | Illinois controlled-substance schedule | Unscheduled (720 ILCS 570) | | Prescription required | Yes (standard Rx, no special form) | | 503A compounding permitted | No (not on FDA 503A Bulks List) | | 503B compounding permitted | No (not on FDA 503B Bulks List) | | Telehealth prescribing | Permitted under 20 ILCS 3960 | | Off-label prescribing | Permitted (225 ILCS 60) | | "Research chemical" purchase | Not legal for human use under FDCA |